{"title":"通过网络药理学和分子对接验证探讨多刺草治疗肝癌的机制。","authors":"Nan Wang, Liwen Tang, Ronghui Duan, Yuhong Shu","doi":"10.1159/000542990","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hedysarum Multijugum Maxim (HMM), a Chinese traditional medicine , exerts anti-tumor effects and has been extensively studied for its potential to treat cancer in recent years. Clinical research has shown that HMM can control hepatocellular cancer, but the exact molecular mechanism is unclear.</p><p><strong>Methods: </strong>To identify the principal bioactive constituents of HMM and their corresponding targets, we constructed a protein-protein interaction (PPI) network. Secondly, the Cytoscape software was utilized to delineate the relationships among drugs, active components, targets, and illnesses. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis using the clusterProfiler tools on the DAVID platform and the Bioconductor package in R. Molecular docking was performed on the PubChem database, whereas the AutoDock, and PyMOL software were utilized to explore the binding affinity of the primary targets and active molecules.</p><p><strong>Results: </strong>Network pharmacology and molecular docking analyses identified six key active constituents of HMM: quercetin, kaempferol, formononetin, isorhamnetin, calycosin, and 7-O-methylisomucronulatol. It was predicted that this herb can modulate the expression of several genes, including TP53, AKT1, MYC, CASP3, VEGFA, EGFR, HIF1A, ESR1, CCND1, and PTGS2.</p><p><strong>Conclusion: </strong>HMM has potential therapeutic effects on the liver cancer. This study provides important insights regarding the methods for investigating HMM in the treatment of hepatocellular cancer.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-24"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigating the Mechanism of Hedysarum Multijugum Maxim in the Treatment of Liver Cancer through Network Pharmacology and Molecular Docking Validation.\",\"authors\":\"Nan Wang, Liwen Tang, Ronghui Duan, Yuhong Shu\",\"doi\":\"10.1159/000542990\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Hedysarum Multijugum Maxim (HMM), a Chinese traditional medicine , exerts anti-tumor effects and has been extensively studied for its potential to treat cancer in recent years. Clinical research has shown that HMM can control hepatocellular cancer, but the exact molecular mechanism is unclear.</p><p><strong>Methods: </strong>To identify the principal bioactive constituents of HMM and their corresponding targets, we constructed a protein-protein interaction (PPI) network. Secondly, the Cytoscape software was utilized to delineate the relationships among drugs, active components, targets, and illnesses. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis using the clusterProfiler tools on the DAVID platform and the Bioconductor package in R. Molecular docking was performed on the PubChem database, whereas the AutoDock, and PyMOL software were utilized to explore the binding affinity of the primary targets and active molecules.</p><p><strong>Results: </strong>Network pharmacology and molecular docking analyses identified six key active constituents of HMM: quercetin, kaempferol, formononetin, isorhamnetin, calycosin, and 7-O-methylisomucronulatol. It was predicted that this herb can modulate the expression of several genes, including TP53, AKT1, MYC, CASP3, VEGFA, EGFR, HIF1A, ESR1, CCND1, and PTGS2.</p><p><strong>Conclusion: </strong>HMM has potential therapeutic effects on the liver cancer. This study provides important insights regarding the methods for investigating HMM in the treatment of hepatocellular cancer.</p>\",\"PeriodicalId\":19497,\"journal\":{\"name\":\"Oncology\",\"volume\":\" \",\"pages\":\"1-24\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000542990\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542990","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
摘要:海麻草(Hedysarum Multijugum Maxim, HMM)是一种具有抗肿瘤作用的中药,近年来因其治疗癌症的潜力而被广泛研究。临床研究表明HMM可以控制肝细胞癌,但确切的分子机制尚不清楚。方法:为了鉴定HMM的主要生物活性成分及其相应的靶点,我们构建了一个蛋白质-蛋白质相互作用(PPI)网络。其次,利用Cytoscape软件描述药物、活性成分、靶点和疾病之间的关系。利用DAVID平台的clusterProfiler工具和R.的Bioconductor软件包进行基因本体(GO)分析和京都基因与基因组百科全书(KEGG)富集分析,在PubChem数据库上进行分子对接,利用AutoDock和PyMOL软件探索主要靶点和活性分子的结合亲和力。结果:通过网络药理学和分子对接分析,鉴定出槲皮素、山奈酚、刺芒柄花素、异鼠李素、毛蕊花素和7- o -甲基异多环醛酸酯6种关键活性成分。据预测,该草药可以调节几种基因的表达,包括TP53、AKT1、MYC、CASP3、VEGFA、EGFR、HIF1A、ESR1、CCND1和PTGS2。结论:HMM对肝癌有潜在的治疗作用。本研究为研究HMM治疗肝细胞癌的方法提供了重要的见解。
Investigating the Mechanism of Hedysarum Multijugum Maxim in the Treatment of Liver Cancer through Network Pharmacology and Molecular Docking Validation.
Introduction: Hedysarum Multijugum Maxim (HMM), a Chinese traditional medicine , exerts anti-tumor effects and has been extensively studied for its potential to treat cancer in recent years. Clinical research has shown that HMM can control hepatocellular cancer, but the exact molecular mechanism is unclear.
Methods: To identify the principal bioactive constituents of HMM and their corresponding targets, we constructed a protein-protein interaction (PPI) network. Secondly, the Cytoscape software was utilized to delineate the relationships among drugs, active components, targets, and illnesses. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis using the clusterProfiler tools on the DAVID platform and the Bioconductor package in R. Molecular docking was performed on the PubChem database, whereas the AutoDock, and PyMOL software were utilized to explore the binding affinity of the primary targets and active molecules.
Results: Network pharmacology and molecular docking analyses identified six key active constituents of HMM: quercetin, kaempferol, formononetin, isorhamnetin, calycosin, and 7-O-methylisomucronulatol. It was predicted that this herb can modulate the expression of several genes, including TP53, AKT1, MYC, CASP3, VEGFA, EGFR, HIF1A, ESR1, CCND1, and PTGS2.
Conclusion: HMM has potential therapeutic effects on the liver cancer. This study provides important insights regarding the methods for investigating HMM in the treatment of hepatocellular cancer.
期刊介绍:
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.